15:31 , May 25, 2018 |  BC Week In Review  |  Clinical News

Bavarian Nordic's ProstVac misses OS endpoint in Phase III for CRPC

Bavarian Nordic A/S (CSE:BAVA) said ProstVac rilimogene galvacirepvec alone and in combination with GM-CSF both missed the primary endpoint of improving overall survival (OS) vs. placebo in the Phase III PROSPECT trial to treat metastatic...
23:13 , Sep 15, 2017 |  BC Extra  |  Financial News

Bavarian Nordic plummets on Phase III CRPC failure of ProstVac

Bavarian Nordic A/S (CSE:BAVA) sank DKK213.50 (48%) to DKK230, losing DKK6.8 billion ($1.1 billion) in market cap, on Friday after an IDMC recommended discontinuing for futility the Phase III PROSPECT trial of ProstVac rilimogene galvacirepvec...
21:09 , Sep 15, 2017 |  BC Week In Review  |  Clinical News

IDMC recommends discontinuation of Phase III CRPC of ProstVac

Bavarian Nordic A/S (CSE:BAVA) said an IDMC recommended discontinuing for futility the Phase III PROSPECT trial of ProstVac rilimogene galvacirepvec to treat metastatic castration-resistant prostate cancer (CRPC) based on a preplanned interim analysis. The primary...
23:17 , Sep 14, 2017 |  BC Extra  |  Clinical News

IDMC recommends discontinuation of Phase III CRPC trial of ProstVac

Bavarian Nordic A/S (CSE:BAVA) said an IDMC recommended discontinuing for futility the Phase III PROSPECT trial of ProstVac rilimogene galvacirepvec to treat metastatic castration-resistant prostate cancer based on a preplanned interim analysis. The primary endpoint...
00:20 , Jul 8, 2017 |  BioCentury  |  Finance

A clinical quarter

Buysiders will find themselves digesting at least 23 Phase III data readouts in the next quarter, two of which could provide clarity on increasingly competitive markets in lung cancer and hemophilia. The third quarter is...
21:50 , Apr 20, 2017 |  BC Week In Review  |  Clinical News

ProstVac: Ph I/II started

Bavarian Nordic said NCI investigators began an open-label, U.S. Phase I/II trial to evaluate ProstVac plus Opdivo nivolumab and Yervoy ipilimumab in about 65 patients. The Phase I portion will enroll 10 patients with castration-resistant...
00:53 , Dec 31, 2016 |  BioCentury  |  Finance

Delivering takeouts

  BioCentury’s 25th annual Buyside View finds biotech investors focusing on mid-cap names with late-stage or marketed products that could become M&A targets. “The main theme playing at the moment is investors like us are...
07:00 , Oct 17, 2016 |  BC Week In Review  |  Clinical News

Rilimogene galvacirepvec: Phase II started

Bavarian Nordic said investigators began an open-label, U.S. Phase II trial to evaluate subcutaneous ProstVac and IV Yervoy ipilimumab each as monotherapy or in combination in 75 patients undergoing radical prostatectomy. Patients will receive ProstVac...
08:00 , Jan 11, 2016 |  BioCentury  |  Finance

Sowing season

Stephen Hansen, Associate Editor   BUYSIDE VIEW XXIV While the biotech sector's three-year rocket ride isn't likely to continue in 2016, fund managers are still anticipating a slew of high-profile milestones in the New Year....
07:00 , Aug 10, 2015 |  BC Week In Review  |  Clinical News

Rilimogene galvacirepvec: Phase II started

Bavarian Nordic said the NCI began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate subcutaneous ProstVac given on days 0, 14, 28, 56, 84, 112 and 140 in about 90 patients undergoing active surveillance....